Nevada
|
0-30379
|
88-0425691
|
(State or Other Jurisdiction of Incorporation or Organization)
|
(Commission File Number)
|
(I.R.S. Employer Identification No.)
|
☐
|
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
|
☐
|
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
|
☐
|
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
|
☐
|
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
|
Title of each class
|
|
Trading Symbol
|
|
Name of each exchange on which registered
|
Common Stock, $0.01 par value
|
|
CEMI
|
|
The NASDAQ Stock Market LLC
|
Item 1.01 |
Entry Into a Material Definitive Agreement.
|
Item 5.02 |
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.
|
Item 9.01 |
Financial Statements and Exhibits.
|
Exhibit
|
|
Description
|
Amendment No. 1 dated February 9, 2022 between Chembio Diagnostics, Inc. and Richard L. Eberly, amending the Employment Agreement dated March 4, 2020
|
||
104
|
Cover Page Interactive Data File (embedded within the XBRL document)
|
|
Chembio Diagnostics, Inc.
|
|
|
|
|
Dated: February 14, 2022
|
By:
|
/s/ Lawrence J. Steenvoorden
|
|
Executive Vice President and Chief Financial Officer
|
|
“6.8 |
Termination Related to Change in Control. In the event of the
termination of the Executive’s employment by the Company without Cause or by the Executive for Good Reason or of the expiration of the Term upon notice of nonrenewal delivered by the Company in accordance with Section 1, then, in each of the foregoing cases within twelve months following a Change in Control, the Executive shall, subject to Section 6.7, be entitled to receive, in addition to the Base Obligations and the Severance Benefits, the accelerated vesting in full of each and every outstanding equity award agreement executed by the Executive and the Company, to the extent such vesting is based solely upon the Executive’s continued service over a period of
time (rather than upon any Company, Executive or other performance-related metric).”
|
Richard L. Eberly | Chembio Diagnostics, Inc. | |
|
|
|
/s/ Richard L. Eberly
|
By:
|
/s/ Lawrence J. Steenvoorden
|
|
|
Lawrence J. Steenvoorden |
|
|
Chief Financial Officer and |
|
|
Executive Vice President
|